• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    New EU Ovarian Cancer Diagnostic Approval Could Be A Game Changer For Agilent Technologies (A)

    Simply Wall St·08/05/2026 22:30:18
    Listen to the news
    • Agilent Technologies recently received European regulatory certification for its PD-L1 IHC 22C3 pharmDx test as a companion diagnostic in certain ovarian cancers, supporting identification of patients who may benefit from Merck’s Keytruda therapy.
    • This cancer-specific approval enhances Agilent’s position in immuno-oncology diagnostics and deepens its collaboration with Merck, potentially broadening its clinical testing footprint across Europe.
    • We’ll now explore how this new European ovarian cancer companion diagnostic approval could shape Agilent’s investment narrative in diagnostics growth.

    Uncover the next big thing with 19 elite penny stocks that balance risk and reward.

    Agilent Technologies Investment Narrative Recap

    To own Agilent, you need to believe its mix of analytical instruments and higher value diagnostics can support steady growth while absorbing tariff and supply chain pressures. The new European ovarian cancer companion diagnostic approval reinforces the diagnostics story but does not materially change the near term catalysts, which still center on execution against 2026 revenue guidance, nor does it ease key risks around margin pressure from tariffs and competitive intensity.

    The most relevant recent announcement here is Agilent’s March 26 FDA approval of PD L1 IHC 22C3 pharmDx as a companion diagnostic for multiple tumor types with Keytruda. Taken together with the new European ovarian cancer certification, it points to a pattern of incremental regulatory clearances that could support test adoption, even as options markets signal expectations of sharp stock moves around upcoming catalysts.

    Yet investors should also be aware that rising tariff driven costs and supply chain complexity could...

    Read the full narrative on Agilent Technologies (it's free!)

    Agilent Technologies’ narrative projects $8.8 billion revenue and $2.1 billion earnings by 2029. This requires 6.7% yearly revenue growth and about a $0.7 billion earnings increase from $1.4 billion today.

    Uncover how Agilent Technologies' forecasts yield a $161.00 fair value, a 14% upside to its current price.

    Exploring Other Perspectives

    A 1-Year Stock Price Chart
    A 1-Year Stock Price Chart

    Four members of the Simply Wall St Community estimate Agilent’s fair value between US$150.54 and US$178.69, underscoring how far opinions can spread. You should weigh these against risks such as tariff driven cost inflation that could pressure margins and shape how the company’s performance ultimately compares with these expectations.

    Explore 4 other fair value estimates on Agilent Technologies - why the stock might be worth just $150.54!

    The Verdict Is Yours

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    • A great starting point for your Agilent Technologies research is our analysis highlighting 3 key rewards that could impact your investment decision.
    • Our free Agilent Technologies research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Agilent Technologies' overall financial health at a glance.

    Want Some Alternatives?

    Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.